Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

This single-arm, multicenter Phase II study assessed the efficacy and safety of olverembatinib in combination with the VP (vindesine+prednisone) regimen (OVP) in the first-line treatment of adult ...

The VEDOSS project has previously shown that 70% of patients with Raynaud's phenomenon and at least one red flag – systemic ...

While foundational HIS models primarily supported lymphoid cells, second-generation host strains expressing human cytokines made HIS models with human innate and adaptive cells possible. While ...

There are two major families of blood cells: the myeloid lineage and the lymphoid lineage. Proper blood composition and function requires that myeloid and lymphoid precursor cells differentiate into ...

All the driver mutations that identified all Philadelphia chromosome (Ph)–positive (Ph+) and Ph-negative neoplasms should be absent, together with all tyrosine kinase gene fusions that identified the ...

Suggested remit: To appraise the clinical and cost effectiveness of pemigatinib within its marketing authorisation for treating myeloproliferative neoplasms with an FGFR1 rearrangement. Please note ...

We observe that the HSC identity is changed towards a myeloid‐biased HSC and show that CD201 is enriched in lymphoid‐biased HSCs. While CD201 expression under steady‐state conditions reveals a ...

Sometimes ALL with myeloid markers may be included under AML called AML with lymphoid markers, or mixed lineage leukemias or undifferentiated or biphenotypic acute leukemias (with both lymphocytic ...